AKT1 and neoplasm: Strikingly, the simultaneous injection of myr-AKT1, TAZS89A, and dnRBP-J did not hamper tumor development in mice, which required to be sacrificed by 13 weeks post-injection due to high tumor burden (Fig. 8B).